Surveillance of Measles and Rubella in Bagmati Province, Nepal: An Analysis of Facilitators and Challenges Through Mixed Methods Research - Takeaways - DentalSpire

Surveillance of Measles and Rubella in Bagmati Province, Nepal: An Analysis of Facilitators and Challenges Through Mixed Methods Research

  • By

  • Bipsana Shrestha

  • Surakshya Kunwar

  • Alina Upreti

  • Kshitij Karki

  • Paras Pangeni

  • Poonam Subedi

  • Leela Khanal

  • Rajeev Shrestha

  • Dipesh Tamrakar

  • Bhim Singh Tinkari

  • Shyam Raj Upreti

  • February 24, 2026

  • 0 min

Share

  • 1

    Measles remains a significant global health issue, with over 9 million cases and 136,000 deaths annually, exacerbated by COVID-19 vaccination disruptions.

  • 2

    Nepal's suspected measles cases decreased from 1417 in 2021 to 1108 in 2022, following the Measles Rubella Supplementary Activities and routine immunization.

  • 3

    The WHO South-East Asia Region aims to eliminate measles and rubella by 2026, revising its target due to challenges like immunity gaps and pandemic impacts.

  • 4

    Nepal's national immunization schedule includes two doses of measles vaccine, achieving 97% coverage for the first dose and 95% for the second as of 2022.

  • 5

    Challenges in Nepal's measles-rubella surveillance include delays in specimen collection and transport, impacting outbreak response and laboratory confirmation.

Original Source(s)

Surveillance of Measles and Rubella in Bagmati Province, Nepal: An Analysis of Facilitators and Challenges Through Mixed Methods Research

  • by Bipsana Shrestha, Surakshya Kunwar, Alina Upreti, Kshitij Karki, Paras Pangeni, Poonam Subedi, Leela Khanal, Rajeev Shrestha, Dipesh Tamrakar, Bhim Singh Tinkari, Shyam Raj Upreti

  • February 24, 2026

Related Content

Emulating target trials of postexposure vaccines using observational data

Persistent Immunity From Historic Smallpox Vaccination and Its Limited Cross-Neutralization of Monkeypox Virus: A Population-based Serological Study in Taiwan

Effectiveness of the 2023 Southern Hemisphere Influenza Vaccine Against Outpatient Influenza-Like Illness: A Multi-Country Test-Negative Design Study